PDL BIOPHARMA INC's ticker is PDLI and the CUSIP is 69329Y104. A total of 193 filers reported holding PDL BIOPHARMA INC in Q4 2016. The put-call ratio across all filers is 0.18 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $497,000 | +18.6% | 157,878 | +9.7% | 0.00% | – |
| Q2 2020 | $419,000 | -10.7% | 143,946 | -13.5% | 0.00% | – |
| Q1 2020 | $469,000 | -14.1% | 166,321 | -1.0% | 0.00% | – |
| Q4 2019 | $546,000 | +75.6% | 168,064 | +17.0% | 0.00% | – |
| Q3 2019 | $311,000 | -82.0% | 143,666 | -73.9% | 0.00% | – |
| Q2 2019 | $1,725,000 | +817.6% | 550,816 | +988.6% | 0.00% | – |
| Q1 2019 | $188,000 | -25.4% | 50,600 | -41.8% | 0.00% | – |
| Q4 2018 | $252,000 | -1.2% | 86,979 | -10.4% | 0.00% | – |
| Q3 2018 | $255,000 | -22.0% | 97,100 | -30.5% | 0.00% | – |
| Q2 2018 | $327,000 | -14.4% | 139,723 | +0.3% | 0.00% | – |
| Q4 2017 | $382,000 | -28.9% | 139,247 | -12.0% | 0.00% | – |
| Q3 2017 | $537,000 | +7.6% | 158,300 | -21.6% | 0.00% | – |
| Q2 2017 | $499,000 | +8.7% | 201,800 | -0.1% | 0.00% | – |
| Q1 2017 | $459,000 | -34.9% | 202,000 | -39.2% | 0.00% | – |
| Q4 2016 | $705,000 | -4.2% | 332,305 | +51.3% | 0.00% | – |
| Q3 2016 | $736,000 | +34.8% | 219,600 | +26.3% | 0.00% | – |
| Q2 2016 | $546,000 | -53.4% | 173,900 | -50.6% | 0.00% | -100.0% |
| Q1 2016 | $1,171,000 | +100.9% | 351,741 | +113.7% | 0.00% | – |
| Q4 2015 | $583,000 | +14.1% | 164,634 | +61.9% | 0.00% | – |
| Q3 2015 | $511,000 | -75.5% | 101,693 | -68.6% | 0.00% | – |
| Q2 2015 | $2,084,000 | +13.9% | 324,113 | +24.6% | 0.00% | – |
| Q1 2015 | $1,829,000 | -8.1% | 260,022 | +0.7% | 0.00% | – |
| Q4 2014 | $1,990,000 | -3.1% | 258,201 | -6.1% | 0.00% | – |
| Q3 2014 | $2,054,000 | -58.0% | 275,002 | -45.6% | 0.00% | -100.0% |
| Q2 2014 | $4,890,000 | +163.0% | 505,201 | +125.9% | 0.00% | – |
| Q1 2014 | $1,859,000 | -76.0% | 223,647 | -75.7% | 0.00% | -100.0% |
| Q4 2013 | $7,754,000 | +199.5% | 918,826 | +182.9% | 0.00% | +200.0% |
| Q3 2013 | $2,589,000 | +211.9% | 324,777 | +202.4% | 0.00% | – |
| Q2 2013 | $830,000 | – | 107,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nine Chapters Capital Management LLC | 119,700 | $254,000 | 0.43% |
| GSA CAPITAL PARTNERS LLP | 1,587,756 | $3,366,000 | 0.20% |
| AMERICAFIRST CAPITAL MANAGEMENT, LLC | 60,901 | $129,110,000 | 0.14% |
| Acrospire Investment Management LLC | 129,480 | $274,000 | 0.11% |
| SECOR Capital Advisors, LP | 410,323 | $870,000 | 0.11% |
| RBF Capital, LLC | 251,421 | $540,000 | 0.08% |
| Park West Asset Management LLC | 400,000 | $848,000 | 0.07% |
| MACKENZIE FINANCIAL CORP | 4,687,825 | $9,938,000 | 0.06% |
| CIGNA INVESTMENTS INC /NEW | 261,533 | $554,000,000 | 0.06% |
| ACADIAN ASSET MANAGEMENT LLC | 5,503,285 | $11,665,000 | 0.06% |